GlassScriptPhysician profile
Alyssa Corrigan
NPI 1255965414
$16,927.03
in general payments reported to CMS, 2019-2025
38 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,517 · 2022: $2,911 · 2023: $5,231 · 2024: $4,591 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $651 · Travel and Lodging: $24.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,822.55 |
| Education | $651.47 |
| Travel and Lodging | $24.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,676.55 | 2021-2025 | |
| Janssen Biotech, INC. | $2,319.10 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,480.47 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $1,396.20 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $1,311.79 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,140.49 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $881.07 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $598.66 | 2021-2025 | |
| Incyte Corporation | $505.66 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $465.69 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $455.63 | 2021-2022 | |
| Galderma Laboratories, L.P. | $415.94 | 2023-2025 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $407.49 | 2021-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $378.31 | 2023-2025 | Zoryve |
| Ucb, INC. | $369.72 | 2021-2025 | Bimzelx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $317.40 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $296.33 | 2023-2024 | Vtama |
| Fresenius Kabi USA, LLC | $262.32 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.23 | 2022-2025 | Cyltezo, Spevigo |
| Sanofi-Aventis U.S. LLC | $189.94 | 2022-2023 | |
| Journey Medical Corporation | $123.09 | 2021 | |
| Epi Health, LLC | $115.75 | 2021-2022 | |
| Biofrontera INC. | $94.41 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $86.47 | 2022-2025 | |
| Smith+Nephew, INC. | $57.18 | 2025 | Grafix Pl |
| Organon LLC | $45.08 | 2025 | |
| Almirall LLC | $43.32 | 2021-2022 | |
| Strata Skin Sciences, INC. | $38.27 | 2022-2024 | Xtrac |
| Kerecis Limited | $37.63 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Verrica Pharmaceuticals INC. | $35.43 | 2025 | Ycanth |
| Novo Nordisk INC | $31.07 | 2025 | Rivfloza |
| Helsinn Therapeutics (U.S.), INC. | $29.47 | 2023-2024 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.92 | 2022 | |
| Nobelpharma America, LLC | $23.47 | 2022 | |
| Lnhc, INC | $18.92 | 2025 | Zelsuvmi |
| Boston Scientific Corporation | $18.58 | 2024 | Advantage System |
| Kyowa Kirin, INC. | $13.54 | 2022 | |
| Organogenesis INC. | $13.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Corrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.